Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Not to be sneezed at - Allergy Therapeutics revenues up 18%

The company, which has developed short course inoculations against hay fever, said turnover was £40.4mln in the six months ended December 31.
Not to be sneezed at - Allergy Therapeutics revenues up 18%
As the name suggests, the company has developed drugs that protect against common allergies

Allergy Therapeutics plc (LON:AGY) said it had gained share in a “flat” European market as it said sales had grown strongly in the first half of its financial year.

The company, which has developed short course inoculations against hay fever, said turnover was £40.4mln in the six months ended December 31.

That represents an increase of 18% at constant currencies or 39% when the translational currency effect of the weak pound is brought into play.

“We are excited by the prospects of the company as we continue expanding our operations in Europe, progressing our development pipeline and moving forward with a world-class portfolio of allergy vaccines,” said chief executive Manuel Llobet.

“We are confident about the full year and look forward to updating shareholders on further progress throughout 2017."

The drug development programme in the US and Europe is proceeding to plan, Allergy said.

Ian_55ae0ddd437b7.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use